WXXWY - WuXi Biologics ImmuneOncia sign MOU for development of anti-PD-L1/CD47 bispecific antibody

WuXi Biologics (OTCPK:WXXWY) and South Korea based ImmuneOncia Therapeutics announce that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47. Within the partnership, ImmuneOncia will have access to WuXi's integrated services in cell line development, cell culture development, biologics manufacturing and bioassay development. WuXi Biologics (OTCPK:WXXWY) will support ImmuneOncia on the whole CMC studies of IOH-001 for Investigational New Drug (IND) application. "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody into clinical development through our integrated services and know-how. At WuXi Biologics, we have demonstrated our extensive capabilities for CMC development, analytical method, and quality control by enabling over 60 bispecific projects," commented Dr. Chris Chen, CEO of WuXi Biologics.

For further details see:

WuXi Biologics, ImmuneOncia sign MOU for development of anti-PD-L1/CD47 bispecific antibody